NCT03439501 is a Phase 2 clinical trial of avelumab in Lymphoma, Extranodal NK-T-Cell, sponsored by Samsung Medical Center.

Who is sponsoring NCT03439501?

NCT03439501 is sponsored by Samsung Medical Center.

What drugs are being tested in NCT03439501?

Interventions in NCT03439501: avelumab.

What condition does NCT03439501 study?

NCT03439501 studies Lymphoma, Extranodal NK-T-Cell.

Is NCT03439501 still recruiting?

NCT03439501 is currently status unknown. Last updated 24 September 2021.

Last reviewed 2021-09-24 · How we verify

NCT03439501

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Avelumab in Relapsed or Refractory Extranodal Natural Killer/T-cell Lymphoma[AVENT STUDY]

Status unknown Phase 2 Last updated 24 September 2021

What this trial tests

Phase 2 trial testing avelumab in Lymphoma, Extranodal NK-T-Cell in 21 participants. Status unknown.

Timeline

16 January 2018

Primary endpoint
30 January 2022

30 March 2022

Quick facts

Lead sponsor	Samsung Medical Center
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	21
Start date	16 January 2018
Primary completion	30 January 2022
Estimated completion	30 March 2022
Sites	1 location across South Korea

Drugs / interventions tested

avelumab (avelumab) — full drug profile →

Conditions studied

Lymphoma, Extranodal NK-T-Cell — all drugs for Lymphoma, Extranodal NK-T-Cell →

Sponsor

Samsung Medical Center

Who can join

20 and older, any sex, with Lymphoma, Extranodal NK-T-Cell. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study was conducted to evaluate the complete response rate of avelumab in patients with NK / T-cell lymphoma besides relapsed or refractory stage lymphoma.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons.
Naimi A, Mohammed RN, Raji A, Chupradit S, et al · · 2022 · cited 350× · PMID 35392976 · DOI 10.1186/s12964-022-00854-y
Avelumab for the treatment of relapsed or refractory extranodal NK/T-cell lymphoma: an open-label phase 2 study.
Kim SJ, Lim JQ, Laurensia Y, Cho J, et al · · 2020 · cited 99× · PMID 32766875 · DOI 10.1182/blood.2020007247
Targeting immune checkpoints: how to use natural killer cells for fighting against solid tumors.
Ghaedrahmati F, Esmaeil N, Abbaspour M. · · 2023 · cited 39× · PMID 36585761 · DOI 10.1002/cac2.12394
Novel target and treatment agents for natural killer/T-cell lymphoma.
Tian XP, Cao Y, Cai J, Zhang YC, et al · · 2023 · cited 19× · PMID 37480137 · DOI 10.1186/s13045-023-01483-9
A systematic review and meta-analysis of immune checkpoint therapy in relapsed or refractory non-Hodgkin lymphoma; a friend or foe?
Davoodi-Moghaddam Z, Jafari-Raddani F, Noori M, Bashash D. · · 2023 · cited 15× · PMID 36773442 · DOI 10.1016/j.tranon.2023.101636
Current Immunotherapeutic Approaches in T Cell Non-Hodgkin Lymphomas.
Poggio T, Duyster J, Illert AL. · · 2018 · cited 13× · PMID 30231561 · DOI 10.3390/cancers10090339
Advances and challenges of immunotherapies in NK/T cell lymphomas.
He L, Chen N, Dai L, Peng X. · · 2023 · cited 12× · PMID 38026157 · DOI 10.1016/j.isci.2023.108192
B7 Family Members in Lymphoma: Promising Novel Targets for Tumor Immunotherapy?
Zhang W, Qiu Y, Xie X, Fu Y, et al · · 2021 · cited 7× · PMID 33869045 · DOI 10.3389/fonc.2021.647526

Verify or expand the search:

Other trials of avelumab

Trials testing the same drug.

NCT05650164 — Treatment Outcomes in Japanese RCC Patients Treated With Avelumab Plus Axitinib as First-line Therapy: Retrospective Stu · completed
NCT05012865 — Current Treatment Outcomes in Japanese RCC Patients Treated With Avelumab Plus Axitinib as First-line Therapy: Retrospec · completed
NCT05394493 — An Observational Chart Review Study To Describe The Real-World Outcomes And Use Of Avelumab In Combination With Axitinib · completed
NCT04052204 — Avelumab With Bempegaldesleukin With or Without Talazoparib or Enzalutamide in Advanced or Metastatic Solid Tumors · Phase 1, PHASE2 · terminated
NCT03563170 — QUILT-3.072: NANT Hepatocellular Carcinoma (HCC) Vaccine · Phase 1, PHASE2 · withdrawn

Other Samsung Medical Center trials

Trials by the same sponsor.

NCT07482865 — Routine Versus Provisional Distal Perfusion Catheter Placement in Patients Undergoing Mechanical Circulatory Support · NA · not yet recruiting
NCT07467213 — Routine Use of Potassium Competitive Acid Blocker vs. Guideline-Directed Gastrointestinal Protection Strategy in Acute M · Phase 4 · not yet recruiting
NCT07530913 — Effectiveness Analysis of a Rehabilitation Exercise Platform for Living Donor Liver Transplantation Patients · NA · enrolling by invitation
NCT07500701 — Salvage Moderate Hypofractionated Versus Ultrahypofractionated Radiotherapy for Biochemical Recurrence After Radical Pro · Phase 3 · recruiting
NCT07409441 — Korea Acute Myocardial Infarction Registry · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03439501 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Samsung Medical Center
Last refreshed: 24 September 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03439501.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing